Bristol Myers Squibb Canada (BMS) today announced that Canada's Drug Agency (CDA-AMC) has issued a positive reimbursement recommendation for OPDIVO® (nivolumab) in combination with YERVOY® (ipilimumab ...

Bristol Myers Squibb (NYSE: BMY) is bringing fresh participants into its Phase III ADEPT-2 trial of Cobenfy ...

San Diego–based Ventyx Biosciences has what pharma wants, according to William Blair: two NLRP3 inhibitors for inflammatory ...

This initiative marks among the BMS Foundation’s first grants in India to increase access to screening and build capacity to ...

Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for ...

Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor ...

As the digital world surges forward, data centers have become the silent engines powering our daily lives—but at a steep ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

Australia is at a new frontier of property and infrastructure investment, one in which investors don’t require sweeping views ...

This month's LCGC Blog from Jonnie Shackman from the America Chemical Society (ACS) reflects on how early experiences with computer programming shaped the author’s understanding of fundamental logic, ...

Detailed price information for Aerovironment Inc (AVAV-Q) from The Globe and Mail including charting and trades.

Bristol-Myers Squibb shares gained after the company announced that it will enroll additional patients in the ADEPT-2 study.